Monte Rosa Therapeutics, Inc. GLUE Increase (Decrease) in Other Receivables
Increase (Decrease) in Other Receivables at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherReceivables.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s increase (decrease) in other receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s increase (decrease) in other receivables?
- Monte Rosa Therapeutics, Inc. (GLUE) reported increase (decrease) in other receivables of $9K in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s increase (decrease) in other receivables changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s increase (decrease) in other receivables decreased by 99.3% year-over-year, from $1.24M to $9K.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s increase (decrease) in other receivables?
- Over 2 years (2022 to 2025), Monte Rosa Therapeutics, Inc.'s increase (decrease) in other receivables has grown at a 406.2% compound annual growth rate (CAGR), from $187K to $4.79M.